(Q36106736)

12 August 2017

1 reference

title

Benefit-risk assessment of irinotecan in advanced colorectal cancer (English)

1 reference

12 August 2017

1 reference

1 reference

1

Bengt Glimelius

1 reference

12 August 2017

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

28

1 reference

12 August 2017

5

1 reference

12 August 2017

417-433

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200528050-00005

12 August 2017

0 references

cites work

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

1 reference

12 December 2020

Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.

1 reference

12 December 2020

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer

1 reference

12 December 2020

Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study

1 reference

12 December 2020

Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.

1 reference

12 December 2020

A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma

1 reference

12 December 2020

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

12 December 2020

Epidemiology of colorectal cancer

1 reference

12 December 2020

Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen

1 reference

12 December 2020

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein

1 reference

12 December 2020

Cost of Treating Advanced Colorectal Cancer: A Retrospective Comparison of Treatment Regimens

1 reference

12 December 2020

In vitro activation of irinotecan to SN-38 by human liver and intestine

1 reference

12 December 2020

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group

1 reference

12 December 2020

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Quality of life in patients with advanced colorectal cancer: what has been learnt?

1 reference

12 December 2020

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

12 December 2020

Focus on the individual--quality of life assessments in oncology

1 reference

12 December 2020

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

12 December 2020

CPT-11-induced cholinergic effects in cancer patients

1 reference

12 December 2020

Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study

1 reference

12 December 2020

Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.

1 reference

12 December 2020

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

12 December 2020

Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer.

1 reference

12 December 2020

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

1 reference

12 December 2020

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study

1 reference

12 December 2020

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

12 December 2020

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer

1 reference

12 December 2020

The Swedish Council on Technology Assessment in Health Care (SBU) report on Cancer Chemotherapy--Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation

1 reference

12 December 2020

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

1 reference

12 December 2020

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea

1 reference

12 December 2020

Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein

1 reference

12 December 2020

Economic aspects of chemotherapy

1 reference

12 December 2020

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

1 reference

12 December 2020

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

12 December 2020

Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-

1 reference

12 December 2020

Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer

1 reference

12 December 2020

A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence

1 reference

12 December 2020

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

12 December 2020

Cost-effectiveness of irinotecan in advanced colorectal cancer

1 reference

12 December 2020

Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer

1 reference

12 December 2020

Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters

1 reference

12 December 2020

1 reference

12 December 2020

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups

1 reference

12 December 2020

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

12 December 2020

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

12 December 2020

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

1 reference

12 December 2020

Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention.

1 reference

12 December 2020

Surgery and Local Treatments of Liver Metastases from Colorectal Cancer: How to Improve Results

1 reference

12 December 2020

Toxicity of irinotecan in patients with colorectal cancer

1 reference

12 December 2020

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

1 reference

12 December 2020

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

1 reference

12 December 2020

Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients

1 reference

12 December 2020

Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage

1 reference

12 December 2020

Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer

1 reference

12 December 2020

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

12 December 2020

A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer

1 reference

12 December 2020

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

1 reference

12 December 2020

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

1 reference

12 December 2020

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

12 December 2020

Irinotecan pharmacogenetics: is it time to intervene?

1 reference

12 December 2020

Chemotherapy for colorectal cancer

1 reference

12 December 2020

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer

1 reference

12 December 2020

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

12 December 2020

5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group

1 reference

12 December 2020

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

12 December 2020

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

12 December 2020

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer

1 reference

12 December 2020

A systematic overview of chemotherapy effects in colorectal cancer

1 reference

12 December 2020

Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer

1 reference

12 December 2020

Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase

1 reference

12 December 2020

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation

1 reference

12 December 2020

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

1 reference

12 December 2020

Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer

1 reference

12 December 2020

CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues

1 reference

12 December 2020

Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer

1 reference

12 December 2020

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

Palliative Treatment of Patients with Colorectal Cancer

1 reference

12 December 2020

Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group

1 reference

12 December 2020

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

12 December 2020

10.2165/00002018-200528050-00005

Identifiers

DOI

1 reference

PubMed ID

15853443

Dimensions Publication ID

12 August 2017

0 references

1 reference

PubMed ID

15853443